



[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
National Institutes of Health

CENTER FOR SCIENTIFIC REVIEW Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Center for Scientific Review Special Emphasis Panel  
Member Conflict: Cancer Therapeutics

**Date:** May 22, 2013

**Time:** 1:00 PM to 4:00 PM

**Agenda:** To review and evaluate grant applications

**Place:** National Institutes of Health  
6701 Rockledge Drive  
Bethesda, MD 20892  
(Telephone Conference Call)

**Contact Person:** Careen K Tang-Toth, PHD  
Scientific Review Officer  
Center for Scientific Review  
National Institutes of Health  
6701 Rockledge Drive, Room 6214, MSC 7804  
Bethesda, MD 20892  
(301)435-3504  
[tothct@csr.nih.gov](mailto:tothct@csr.nih.gov)

**Name of Committee:** Oncology 2 - Translational Clinical Integrated Review Group  
Basic Mechanisms of Cancer Therapeutics Study Section  
**Date:** May 24, 2013  
**Time:** 8:00 AM to 5:00 PM  
**Agenda:** To review and evaluate grant applications  
**Place:** Four Season Hotel Washington DC  
2800 Pennsylvania Avenue  
Washington, DC 20007

**Contact Person:** Lambratu Rahman Sesay, PHD  
Scientific Review Officer  
Center for Scientific Review  
National Institutes of Health  
6701 Rockledge Drive, Room 6214, MSC 7804  
Bethesda, MD 20892  
301-451-3493  
rahman-sesayl@csr.nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine;  
93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-  
93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 24, 2013

---

David Clary, Program Analyst  
Office of Federal Advisory Committee Policy

[FR Doc. 2013-10096 Filed 04/29/2013 at 8:45 am; Publication  
Date: 04/30/2013]